Goldman Sachs
DXCM icon

Goldman Sachs’s DexCom DXCM Stock Holding History

Goldman Sachs’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.3M Sell
287,300
-188,100
-40% -$12.5M ﹤0.01% 2667
2026
Q1 		$29.9M Sell
475,400
-59,200
-11% -$4.12M ﹤0.01% 2069
2025
Q4 		$35.5M Buy
534,600
+152,600
+40% +$9.87M ﹤0.01% 1797
2025
Q3 		$25.7M Buy
382,000
+53,700
+16% +$4.25M ﹤0.01% 2007
2025
Q2 		$28.7M Buy
328,300
+153,700
+88% +$12M ﹤0.01% 1801
2025
Q1 		$11.9M Buy
+174,600
New +$14.2M ﹤0.01% 2528
2024
Q4 		– Sell
-15,000
Closed -$1.01M – 6084
2024
Q3 		$1.01M Sell
15,000
-3,000
-17% -$246K ﹤0.01% 4629
2024
Q2 		$2.04M Buy
18,000
+15,000
+500% +$1.9M ﹤0.01% 3897
2024
Q1 		$416K Sell
3,000
-3,600
-55% -$453K ﹤0.01% 4832
2023
Q4 		$819K Buy
+6,600
New +$674K ﹤0.01% 4494
2023
Q3 		– Sell
-40,000
Closed -$5.14M – 5623
2023
Q2 		$5.14M Buy
+40,000
New +$4.84M ﹤0.01% 3089
2022
Q3 		– Sell
-50,000
Closed -$3.73M – 6325
2022
Q2 		$3.73M Buy
+50,000
New +$4.56M ﹤0.01% 3456
2022
Q1 		– Sell
-237,600
Closed -$31.9M – 6632
2021
Q4 		$31.9M Buy
237,600
+186,400
+364% +$26.8M 0.01% 1711
2021
Q3 		$7M Hold
51,200
– – ﹤0.01% 3060
2021
Q2 		$5.47M Hold
51,200
– – ﹤0.01% 3263
2021
Q1 		$4.6M Sell
51,200
-54,000
-51% -$5.07M ﹤0.01% 3210
2020
Q4 		$9.72M Buy
105,200
+33,600
+47% +$3M ﹤0.01% 2489
2020
Q3 		$7.38M Buy
71,600
+58,000
+426% +$6.06M ﹤0.01% 2583
2020
Q2 		$1.38M Buy
13,600
+3,600
+36% +$322K ﹤0.01% 3736
2020
Q1 		$673K Buy
+10,000
New +$622K ﹤0.01% 4027
2014
Q2 		– Sell
-200,000
Closed -$2.07M – 7011
2014
Q1 		$2.07M Sell
200,000
-5,200
-3% -$53.7K ﹤0.01% 3938
2013
Q4 		$1.82M Sell
205,200
-1,683,600
-89% -$13.3M ﹤0.01% 4174
2013
Q3 		$13.3M Buy
1,888,800
+1,688,800
+844% +$10.7M ﹤0.01% 1959
2013
Q2 		$1.12M Buy
+200,000
New +$958K ﹤0.01% 4287

Other funds holding DXCM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Goldman Sachs's DXCM Position: Q2 2026 in Review

Goldman Sachs increased its DexCom (DXCM) stake by 23% in Q2 2026, buying an estimated $47.6M and bringing the position to 3,758,616 shares worth $253M. The position accounts for 0.02% of the portfolio, ranked #668.

Goldman Sachs first reported a position in DXCM in Q2 2013 and has held it in 53 quarters since. The position peaked at $495M in Q2 2020. 973 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Goldman Sachs held 3,758,616 shares of DexCom worth $253M as of Q2 2026.
  • Goldman Sachs bought 714,981 DexCom shares in Q2 2026, an estimated $47.6M.
  • DexCom made up 0.02% of Goldman Sachs's portfolio in Q2 2026, its #668 holding.
  • Goldman Sachs first reported a position in DexCom in Q2 2013 and has held it in 53 quarters since.
  • Goldman Sachs's DexCom position peaked at $495M in Q2 2020.
  • 973 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.